Biogen Alzheimer's Drug Shows Mixed Results

Biogen announced on May 14th that its experimental Alzheimer's drug, diranersen, will advance to late-stage development following a mid-stage trial. The study indicated that the drug slowed cognitive decline and significantly reduced tau protein, a key marker associated with Alzheimer's disease.

Despite these positive indicators, Biogen's stock experienced a nearly 5% decline. This was attributed to the trial failing to show that higher doses of diranersen were more effective than lower doses on a standard dementia severity scale.

Diranersen operates by blocking tau protein production, which disrupts brain cell communication and contributes to cognitive impairment. Patients receiving the drug demonstrated notable reductions in tau, with the most pronounced cognitive effects observed at the lowest dose tested.

Analysts expressed a mixed view, acknowledging the potential cognitive benefits but raising concerns over the lack of detailed quantitative results. Biogen, however, remains confident in the data and plans to present full study findings at a medical conference later this year.